

PRODUCT LIST 2023



The Essential
is Inside

ACTIVE PHARMACEUTICAL INGREDIENTS

NAME	THERAPEUTIC CATEGORY	CAS RN
◦ ◦ ALFUZOSIN HCl	Antihypertensive, Treatment of BPH	[81403-68-1]
◦ ◦ BRIMONIDINE TARTRATE	Antiglaucoma	[70359-46-5]
◦ BROMFENAC SODIUM	Nonsteroidal ocular anti-inflammatory	[120638-55-3]
◦ BUTAMIRATE CITRATE	Antitussive	[18109-81-4]
◦ CHLORPROTHIXENE HCl	Antipsychotic	[6469-93-8]
◦ DOFETILIDE	Antiarrhythmic	[115256-11-6]
◦ ESZOPICLONE	Sedative, Hypnotic	[138729-47-2]
◦ HYMECROMONE	Choleretic and antispasmodic	[90-33-5]
◦ ◦ MOXONIDINE	Antihypertensive	[75438-57-2]
◦ REGADENOSON MONOHYDRATE	Coronary vasodilator	[875148-45-1]
◦ REGADENOSON ANHYDROUS	Coronary vasodilator	[313348-27-5]
◦ RILUZOLE	Neuroprotective	[1744-22-5]
◦ ◦ ◦ RIVAROXABAN	Anticoagulant	[366789-02-8]
◦ TIZANIDINE HYDROCHLORIDE	Muscle relaxant (skeletal)	[64461-82-1]
◦ WARFARIN SODIUM SALT (clathrate)	Anticoagulant	[67430-45-9]
◦ ◦ ZOLPIDEM TARTRATE	Hypnotic	[99294-93-6]
◦ ◦ ZOPICLONE	Sedative, Hypnotic	[43200-80-2]



- DMF available
- ◦ DMF + CEP available
- ◦ ◦ Pipeline



Products protected by valid patents and supplementary protection certificates are not offered for sale in countries where the sale of such products constitutes patent/SPC infringement. We are prepared to closely cooperate with our clients in order to avoid any liability claims based on patent/SPC infringement.



ver.: 2023/v1

WWW.FARMAK.CZ

PRODUCT LIST

2023



The Essential
is Inside

ACTIVE PHARMACEUTICAL INGREDIENTS – CONTRACT PRODUCTION

NAME	THERAPEUTIC CATEGORY	CAS RN
DOXAZOSIN MESYLATE	Antihypertensive, Treatment of BHP	[77883-43-3]
ENZALUTAMIDE	Endocrine therapy	[915087-33-1]
NINTEDANIB	Antineoplastic drugs	[928326-83-4]
SACUBITRIL SODIUM SALT	Antihypertensive	[149690-05-1]
VALSARTAN DISODIUM SALT	Antihypertensive	[391230-93-6]
WARFARIN SODIUM SALT (amorphous)	Anticoagulant	[129-06-6]

NOTE: FARMAK, a.s. is CMO for all above mentioned products and is not competent to provide any commercial or marketing data. For more information please visit our website www.farmak.cz > Products > Contract Production or contact us on info@farmak.cz



Products protected by valid patents and supplementary protection certificates are not offered for sale in countries where the sale of such products constitutes patent/SPC infringement. We are prepared to closely cooperate with our clients in order to avoid any liability claims based on patent/SPC infringement.



ver.: 2023/v1

WWW.FARMAK.CZ

PIPELINE 2023



The Essential
is Inside

ACTIVE PHARMACEUTICAL INGREDIENTS

NAME	THERAPEUTIC CATEGORY	CAS RN
TAFAMIDIS MEGLUMINE	Cardiovascular agents	[951395-08-7]
RIPASUDIL HYDROCHLORIDE DIHYDRATE	Ophthalmology	[887375-67-9]
DARIDOREXANT	Sedatives/Hypnotics	[1505484-82-1]
LUMATEPERONE	Antipsychotics	[313368-91-1]
ERGOTAMINE TARTRATE	Antimigraine agents	[379-79-3]
DIHYDROERGOTAMINE MESYLATE	Antimigraine agents	[6190-39-2]
BUTORPHANOL TARTRATE	Analgesics	[58786-99-5]
DRONABINOL	Analgesics	[1972-08-3]



Disclaimer: You acknowledge that these products cannot be supplied into countries in which their use and/or commercialization may be in conflict with existing IP rights of a third party. In any event, any use and/or commercialization in breach of the above will be made under your and/or the final buyer's (as the case may be) sole responsibility, and you will (and will procure that the final buyer will, as the case may be) keep us fully indemnified and harmless from any claims and consequences arising out of such commercialization, use and breach.



Printed: 2023
ver.: 2023

WWW.FARMAK.CZ